Use of an anti-CD200 antibody for prolonging the survival of allografts: A patent evaluation of WO2012106634A1

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 3, 2013, Pages 389-392

  Rygiel, Tomasz P ^a   Luijk, Bart ^b   Meyaard, Linde ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Allograft; CD200; CD200 receptor; Immunosupression; Transplantation

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD200 ANTIBODY; CD200 RECEPTOR; CYCLOSPORIN; FC RECEPTOR; INTERLEUKIN 12; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CLINICAL EVALUATION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MONOTHERAPY; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SUPPRESSOR CELL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MICE; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84874058577     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.765406     Document Type: Article

References (26)

1. Pritchard NR, Smith KG. B cell inhibitory receptors and autoimmunity. Immunology 2003;108:263-73
2. Wright GJ, Jones M, Puklavec MJ, et al. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001;102:173-9
3. Rijkers ESK, De Ruiter T, Baridi A, et al. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol 2008;45:1126-35
4. Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 2006;79:363-8
5. Karnam G, Rygiel TP, Raaben M, et al. CD200 receptor controls sex-specific TLR7 responses to viral infection. PLoS Pathog 2012;8:e1002710
6. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 2004;173:6786-93
7. Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 2009;183:4879-86
8. Mihrshahi R, Brown MH. Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling. J Immunol 2010;185:7216-22
9. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290:1768-71
10. Rygiel TP, Rijkers ES, De Ruiter T, et al. Lack of CD200 enhances pathological T cell responses during influenza infection. J Immunol 2009;183:1990-6
11. Snelgrove RJ, Goulding J, Didierlaurent AM, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008;9:1074-83
12. Mukhopadhyay S, Pluddemann A, Hoe JC, et al. Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host Microbe 2010;8:236-47
13. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: New approaches to cancer immunotherapy. J Immunol 2007;178:5595-605
14. Rygiel TP, Meyaard L. CD200R signaling in tumor tolerance and inflammation: A tricky balance. Curr Opin Immunol 2012;24:233-8
15. Gorczynski RM, Cattral MS, Chen Z, et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 1999;163:1654-60
16. Gorczynski RM. Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages. Eur J Immunol 2001;31:2331-7
17. Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005;79:1180-3
18. Gorczynski RM, Chen Z, HeW, et al. Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 2009;183:1560-8
19. Yu K, Gorczynski RM. Persistence of gene expression profile in CD200 transgenic skin allografts is associated with graft survival on retransplantation to normal recipients. Transplantation 2012;94:36-42
20. Rygiel TP, Karnam G, Goverse G, et al. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene 2011;31:2979-88
21. Wang JW, Howson JM, Ghansah T, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 2002;295:2094-7
22. Kerr WG. A role for SHIP in stem cell biology and transplantation. Curr Stem Cell Res Ther 2008;3:99-106
23. Chinen J, Buckley RH. Transplantation immunology: Solid organ and bone marrow. J Allergy Clin Immunol 2010;125:S324-35
24. Lunsford KE, Barbas AS, Brennan TV. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. Curr Opin Organ Transplant 2011;16:390-7
25. Kho M, Cransberg K, Weimar W, van Gelder T. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother 2011;12:1217-31
26. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011;91:1057-64